Olopan DS 0.2% is an ophthalmic antiallergic preparation containing Olopatadine, designed to provide effective relief from ocular itching associated with allergic conjunctivitis. With its dual mechanism of action and convenient once-daily dosing, Olopan DS 0.2% helps control allergic eye symptoms while ensuring minimal systemic absorption when used topically.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Olopan DS 0.2% is indicated for the treatment of:

• Ocular itching associated with allergic conjunctivitis

Therapeutic Class

• Ophthalmic Non-Steroid Drugs

Pharmacology

Olopatadine functions as both a mast cell stabilizer and a selective histamine H1 receptor antagonist. It inhibits the release of histamine from mast cells and blocks histamine-mediated effects on human conjunctival epithelial cells. By suppressing type 1 immediate hypersensitivity reactions in both in vivo and in vitro settings, olopatadine effectively reduces allergic inflammation in the eye.
The drug does not exert significant activity on alpha-adrenergic, dopaminergic, or muscarinic (type 1 and 2) receptors. Following topical ocular administration, systemic exposure to olopatadine remains low, contributing to a favorable safety profile.

Dosage and Administration

Dosage should be used as directed by a physician:

• 0.1% Sterile Eye Drops: One drop in each affected eye twice daily at intervals of 6–8 hours

• 0.2% Sterile Eye Drops (Olopan DS): One drop in the affected eye once daily

• 0.7% Sterile Eye Drops: One drop in each affected eye once daily

Drug Interactions

• Concomitant use with central nervous system depressants may result in additive CNS depression.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Olopan DS 0.2% ophthalmic solution is contraindicated in patients with:

• Known hypersensitivity to Olopatadine or any component of the formulation

Side Effects

Headache has been reported in approximately 7% of patients. Other adverse reactions occurring in fewer than 5% of patients include:

• Asthenia

• Blurred vision

• Burning or stinging sensation

• Dry eye

• Foreign body sensation

• Hyperemia

• Hypersensitivity reactions

• Keratitis

• Lid edema

• Nausea

• Pharyngitis

• Pruritus

• Rhinitis

• Sinusitis

• Taste perversion

Pregnancy and Lactation

There are no adequate and well-controlled studies of olopatadine use in pregnant women. Olopan DS 0.2% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether topical ocular administration leads to detectable levels of the drug in human breast milk. Caution is advised when administering to nursing mothers.

Precautions and Warnings

• Not recommended for the treatment of contact lens-related irritation

• Soft contact lenses should be removed before instillation and may be reinserted after at least 10 minutes

Overdose

Symptoms: Drowsiness in adults; in children, initial agitation and restlessness followed by drowsiness
Management: Symptomatic and supportive treatment

Storage Conditions

• Store below 30°C in a cool and dry place

• Protect from light

• Keep out of reach of children

• Avoid touching the dropper tip to prevent contamination

• Discard the product 30 days after first opening

Use in Special Populations

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.